Sign up
DRMA

Dermata Therapeutics Inc (NASDAQ: DRMA)

Healthcare · Biotechnology

——

Quote unavailable · Price data is temporarily unavailable.

Set alert

The Quantellect read. Short interest is 2.56% of float with a 182.54% borrow fee. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 35.5 (overbought above 70, oversold below 30)

Trend—

—

Short interest2.6% of float

FINRA settlement Oct 30, 2026

DRMA price chart

Price — · As of —

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open—
Previous close—
Day range—
52-week range
$0.54 – $3.14Through Nov 18, 2026
Volume—
Average volume (30 calendar days, 0 sessions)
—Through Nov 18, 2026
Market cap$3.06M
P/E (TTM)0.1
Forward P/E—
EPS (TTM)−$4.39
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)0.63

Price history

DRMA · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18

Insufficient data · Tide session Nov 18, 2026

Tide40Calm Tide—
Squeeze23Idle—
How the scores work →

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

— · Analyst consensus not available

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026−$0.55−$0.55—
Q2 2026−$0.55−$0.74—
Q1 2026—−$0.48—
Annual 2025−$1.54−$8.16—
Q3 2025—−$1.65—
Q2 2025—−$1.66—
Q1 2025−$0.45−$0.45—
Annual 2024−$0.32−$8.03—

Smart-money activity

In the last 60 days: 0 insider sales and 0 purchases. Last quarter: 0 new 13F positions. No congressional trades in 90 days.

DateTypeWhoActionAmountSource
Insider sellScott Kathleen D.Sell$13Form 4
Insider buyBedoya-Toro Munera Maria EBuy$1.3KForm 4
Insider buyPROEHL GERALD TBuy$48KForm 4
Insider buyHALE DAVID FBuyUnavailableForm 4
All smart-money activity →

News and press releases

All DRMA news →

Company profile

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

CEO
Mr. Gerald T. Proehl
Headquarters
San Diego, CA, United States
Employees
9
IPO date
Aug 13, 2021
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.